WeVote
Log In

Bill

JA

Bill

HB 6132

Consumer protection: unfair trade practices; insulin drug pricing report; require by the department of attorney general.

2025-2026 Regular Session Introduced by Joey Andrews and 12 co-sponsors

The bill creates a formal AG-led investigation into insulin pricing in Michigan and requires a public report with findings and policy recommendations by Oct 1, 2027.

bill electronically reproduced 06/25/2026
#consumerprotection:unfairtradepractices #health:pharmaceuticals #stateagencies(existing):attorneygeneral
0
WeVote Research Nonpartisan
Bill Summary · HB 6132

Summary of HB 6132 (Michigan, 2025-2026)

Main purpose and intent

  • To strengthen consumer protection related to the pricing of prescription insulin drugs in Michigan.
  • Requires the Attorney General to investigate insulin pricing to ensure adequate protections and to determine whether additional consumer protections are needed.
  • Requires the Attorney General to produce a public report with findings, policy recommendations, and potential bill amendments.

Key provisions and changes

  • Section 9b creates a formal investigation into insulin drug pricing:
    • The Attorney General must investigate pricing of prescription insulin drugs available to Michigan residents.
    • The investigation aims to ensure consumer protections and identify needed protections.
  • Information gathering:
    • The AG shall collect and analyze information from manufacturers, entities involved in the sale of insulin drugs, and others as needed.
    • Publicly available pricing information must be considered.
  • Administrative subpoenas (limited use):
    • If necessary, the AG may issue administrative subpoenas to obtain material, answers, data, or other information.
    • Targeted recipients include other state offices/agencies, pharmacy benefits managers or other carriers, and insulin drug manufacturers in Michigan.
    • Trade secrets exemptions apply; providers may not be required to disclose trade secrets.
  • Public report deadline and contents:
    • By October 1, 2027, the AG must issue a public report detailing findings.
    • The report must be presented to:
    • The Governor
    • Director of the Department of Insurance and Financial Services
    • Standing committees in the Michigan Legislature with primary responsibility for insurance and health policy
    • Required components of the report:
    • (a) Summary of insulin pricing practices and factors influencing pricing of health coverage plans.
    • (b) Public policy recommendations to control and prevent overpricing of prescription insulin drugs.
    • (c) Recommendations for amendments to the Michigan Consumer Protection Act to prevent unfair, unconscionable, or deceptive practices in the sale of prescription insulin drugs, including pricing.
    • (d) Any other information the AG deems necessary.
  • Definitions:
    • “Carrier” aligns with the insurance code definition.
    • “Prescription insulin drug” means a prescription drug containing insulin used to treat diabetes.
    • “Trade secret” follows the Uniform Trade Secrets Act.
  • Effective date:
    • The act takes effect 90 days after enactment.

Who/what is affected

  • Insulin drug manufacturers that provide prescription insulin drugs in Michigan.
  • Pharmacy benefit managers and other carriers involved in insulin drug pricing and coverage.
  • Health insurers and health coverage plans offering insulin drugs to Michigan residents.
  • The general public, through a future AG report and potential legislative recommendations.

Procedural and timeline aspects

  • Introduced and referred to the House Committee on Government Operations on June 25, 2026.
  • Effective date occurs 90 days after enactment.
  • Mandatory public report due by October 1, 2027, with dissemination to key state officials and Legislature.
  • The bill authorizes the AG to use administrative subpoenas as a tool, subject to protection of trade secrets.

Potential impact and considerations

  • Creates a formal, transparent process to scrutinize insulin pricing and its impact on consumers and health plans.
  • May lead to policy recommendations or legislative amendments aimed at curbing insulin price inflation and improving consumer protections.
  • The report could influence state-level discussions on insulin affordability and market practices, including potential changes to the Michigan Consumer Protection Act with respect to pricing practices.
  • Use of subpoenas is limited to non-trade-secret information, balancing investigative needs with confidentiality concerns.

If you’d like, I can provide a side-by-side comparison with current Michigan consumer protection provisions or draft potential stakeholder impact notes for insurers, manufacturers, and patient advocacy groups.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.